STEARDA inhibits arachidonate 5-LO (5-lipoxygenase) with an IC50 of 16 nM. Adiditionally, is an ndogenous fatty acid dopamide that displays 'entourage' effects on endovanilloids NADA and anandamide. STEARDA is inactive at TRPV1 and CB1 receptors (at concentrations up to 5 μM) and does not inhibit AMT or FAAH (IC50 > 25 μM). However, STEARDA potentiates TRPV1-mediated effects of NADA in vitro and in vivo; enhances effects on intracellular Ca2+ (EC50 lowered 3-fold) and nociception. Also, STEARDA inhibits arachidonate 5-lipoxygenase (IC50 = 16 nM).
Chu et al (2003) N-Oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J.Biol.Chem. 278 13633. De Petrocellis et al (2004) Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. Br.J.Pharmacol. 143 251.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.